Release date: August 7, 2017
Expiration date: August 7, 2018
Estimated time to complete activity: 1.0 hour(s)
B. Justin Krawitt, MD
Assistant Professor of Medicine
Assistant Professor of Medicine
Geisel School of Medicine
Hanover, New Hampshire
Medical Director of Care Management, Patient Placement, and Clinical Documentation
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
An estimated 15.7 million adults have been told by a physician or other health professional that they have chronic obstructive pulmonary disease (COPD). Adults with COPD are more likely to be unable to work and have diminished activities of daily living. They also have increased comorbid conditions, difficulty walking or climbing stairs, or need special equipment to manage health problems compared with adults without COPD. Moreover, COPD is the 3rd most common cause of death in the US, just behind cancer and heart disease. Despite significant local and national efforts to reduce the burden of COPD, recent data from the Nationwide Inpatient Sample and Nationwide Emergency Department Sample has revealed that total hospitalizations and emergency department visits for COPD over the past decade have continued to increase. However, COPD is listed as one of the conditions in which hospitalizations are preventable to some degree.
Hospital Medicine Summit (HMS) is an innovative, multi-topic educational initiative designed specifically for hospital-based healthcare providers (hospitalists, internal medicine physicians, physician assistants, nurse practitioners, pharmacists, and nurses). With significant changes occurring in the healthcare system, there is an increased demand on hospital-based healthcare providers to provide care that impacts patients not only in the acute setting, but as they transition back into the community and are managed in the chronic-care healthcare system.
This educational initiative has been designed for hospital-based healthcare providers, including physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists.
Upon completion of this educational activity, participants should be able to:
- Describe long-term management strategies that may reduce COPD related hospital readmissions
- Review important comorbidities of COPD as a part of a management strategy to reduce readmissions
- Incorporate cognitive and physical assessments during inpatient stays and outpatient visits to determine the appropriate device for patients with COPD
- Improve communication between inpatient and outpatient healthcare providers who manage patients with COPD to better coordinate care transitions
Directions to Learner
There are no fees for participating and receiving CME/CE credit for this activity. During the period of August 7, 2017 through August 7, 2018, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number: 0530-9999-17-145-H01-P)
This educational activity for 1.0 contact hours is provided by Global Education Group.
Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Disclosure of Conflicts of Interest
Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education and Global Education Group are committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.
The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
B. Justin Krawitt, MD
Consultant: Sunovion Pharmaceuticals, Inc.
The following planners and managers, Andrea Funk, Liddy Knight, Lindsay Borvansky, Ashley Marostica, RN, MSN, and Patima Tanapat, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education, Global Education Group, Boehringer Ingelheim, Mylan, and Sunovion Pharmaceuticals, Inc., do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Global Education Group, Boehringer Ingelheim, Mylan, and Sunovion Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)
Minimum System Requirements
Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10
Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Flash Player 10
Use of Internet Explorer browser is not recommended.
Click here for more information on minimum system requirements.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.Provider Statement
This CME activity is provided by Integrity Continuing Education.
This activity is jointly provided by Global Education Group and Integrity Continuing Education.
Supported by educational grants from Boehringer Ingelheim, Mylan, and Sunovion Pharmaceuticals, Inc.
- Hospital-based healthcare providers
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.